BioLargo, Inc. filings document an operating company with cleantech, environmental engineering and life sciences subsidiaries, including disclosures tied to product and service revenue, partially owned subsidiaries, debt obligations and common stock. Registration statements and related exhibits describe common stock, capital structure, resale registration rights and equity financing arrangements.
BioLargo's Form 8-K filings record Regulation FD materials, investor presentation exhibits, annual operating-result releases, shareholder town hall transcripts, material definitive agreements and officer compensation converted into common stock. The filings also provide formal disclosure around governance, liquidity, subsidiary activity and risk factors associated with commercializing water treatment, medical technology, engineering services and energy-storage businesses.
BioLargo, Inc. director reports new stock option grants for board service. A company director filed a Form 4 disclosing two stock option awards dated 12/31/2025. One option to purchase 122,084 shares of common stock at an exercise price of $0.1843 per share was granted to replace an earlier option for 45,000 shares that had compensated $22,500 of services and had recently expired unexercised. A second option to purchase 101,736 shares at $0.17 per share was issued as payment of $18,750 in fees for service on the board for the most recently completed quarter under BioLargo’s 2024 Equity Incentive Plan. Both options are exercisable on 12/31/2025 and expire on 12/31/2035, reflecting equity-based compensation to the director instead of cash.
BioLargo, Inc. reported that on November 14, 2025 two company officers agreed to convert an aggregate $99,901 of unpaid salary and unreimbursed business expenses into common stock. The shares were issued at a price of $0.16 per share, resulting in an aggregate issuance of 624,383 shares of BioLargo common stock. These shares are subject to a Lock-Up Agreement dated as of the issuance date, meaning they cannot be sold until BioLargo reports at least $40 million in consolidated gross revenue for any reported period, or its market capitalization exceeds $300 million, or the company undergoes a change in control.
BioLargo, Inc. (BLGO) reported an insider stock acquisition by a director and Chief Science Officer on a Form 4. On 11/14/2025, the reporting person acquired 313,754 shares of common stock at $0.16 per share through an exchange for accrued salary and unreimbursed business expenses. After this transaction, the insider beneficially owns 25,751,505 common shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
The newly issued shares are subject to a lock-up agreement. They cannot be sold until BioLargo reports at least $40 million in gross revenue for any consolidated reporting period, or its market capitalization exceeds $300 million, or there is a change in control of the company.
BioLargo, Inc. (BLGO) reported that a director and officer who is also its President acquired 310,269 shares of common stock on 11/14/2025 at $0.16 per share. The shares were issued by the company in exchange for a reduction of amounts owed to the insider for salary and unreimbursed business expenses.
The newly issued shares are subject to a lock-up agreement and cannot be sold until BioLargo reports at least $40 million in consolidated gross revenue for any period, or its market capitalization exceeds $300 million, or there is a change in control. Following this transaction, the reporting person beneficially owns 10,393,403 shares in total, including 1,528,695 shares held indirectly through a limited liability company.
BioLargo (BLGO) reported a sharply weaker Q3 2025 as a major customer default triggered a large credit loss. Revenue was $1.103 million versus $4.351 million a year ago, with gross profit of $372,000. Operating expenses rose to $7.552 million, including a $3.849 million credit loss expense tied to impaired receivables and a note from a customer following contract and payment disputes now in litigation.
The quarter’s net loss was $7.244 million (vs. $1.060 million). Year to date, revenue was $7.148 million and net loss $11.047 million. Cash and equivalents were $4.546 million with current assets of $5.775 million and current liabilities of $3.451 million, yielding working capital of $2.324 million. The company stated that gross profits for 2025 will not fund operations and raised “substantial doubt” about its ability to continue as a going concern without additional revenue or financing.
Customer concentration remained high, with one customer representing 35% of Q3 revenue and 64% year to date. Cash from financing activities totaled $7.269 million for the first nine months, while operating cash used was $6.707 million. Shares outstanding were 313,762,657 as of November 12, 2025.
BioLargo, Inc. (BLGO) furnished an investor presentation under Item 7.01 (Regulation FD). The company plans to present the slide deck attached as Exhibit 99.1 during an investor webcast on November 14, 2025 at 1:30 PM Pacific Time.
The information is expressly stated as furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act nor incorporated by reference into other filings. The company notes Safe Harbor language applies to forward-looking statements in the slides. Exhibits include 99.1 (slide deck) and 104 (Cover Page Inline XBRL).
BioLargo, Inc. (BLGO) furnished investor presentation materials under Item 7.01 (Regulation FD). The company plans to present the slides attached as Exhibit 99.1 at the LD Micro Main Event XIX at the Hotel del Coronado in San Diego on October 20 at 2:00 p.m. Pacific Time.
The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, is not incorporated by reference into other SEC filings, and may be updated through future public disclosures.
Jack B. Strommen, a director of BioLargo, Inc. (BLGO), received an option grant of 88,235 shares on 09/30/2025 under the company's 2024 Equity Incentive Plan. The option has an exercise price of $0.17 per share, is exercisable beginning 09/30/2025, and expires 09/30/2035. After this grant, Mr. Strommen directly beneficially owns 2,278,121 shares of common stock. The filing states the option was issued as payment for $15,000 of board fees for the most recently completed quarterly period. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and is reported as an individual filing by one reporting person.
Linda Park, a director of Biolargo, Inc. (BLGO), received 110,294 stock options on 09/30/2025 at a $0.17 exercise price that vest/exercise beginning 09/30/2025 and expire 09/30/2035. The filing shows she now directly beneficially owns 1,164,025 shares of common stock after the reported transaction. The options were issued as payment for $18,750 of board fees under the Issuer's 2024 Equity Incentive Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/02/2025.
Christina Elaine Bray, a director of Biolargo, Inc. (BLGO), received an option to purchase 110,294 shares of common stock at an exercise price of $0.17 per share on 09/30/2025. The option is exercisable on 09/30/2025 and expires on 09/30/2035. The filing reports that the option was issued as payment for $18,750 in director fees under the issuer's 2024 Equity Incentive Plan. After this grant, Ms. Bray beneficially owns 1,164,025 shares of Biolargo common stock, held directly. The Form 4 was executed on 10/02/2025 and filed under Section 16 reporting requirements.